Immunotherapy in the Treatment of Non-small Cell Lung Cancer

Overview

Journal Lung Cancer

Specialty Oncology

Date 2014 Jun 2

PMID 24880938

Citations 50

Authors

Raghav Sundar

Richie Soong

Byoung-Chul Cho

Julie R Brahmer

Ross A Soo

Affiliations

Soon will be listed here.

Abstract

Advances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulators, such as CTLA-4, PD-1 and PD-L1 inhibitors in NSCLC have reported promising results with prolonged clinical responses and tolerable toxicity. This article provides an overview of co-stimulatory and inhibitory molecules that regulate the immune response to tumors, recent therapies that have been developed to exploit these interactions and the role of predictive biomarkers in treatment selection.

Citing Articles

Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review.

Lei S, Tian L, Yang L, Yang Y, Li J, Hu X BMC Cancer. 2024; 24(1):1427.

PMID: 39563271 PMC: 11577726. DOI: 10.1186/s12885-024-13155-z.

Comprehensive Analysis for Predicting Prognoses and Immune Responses of m6A-Related lncRNAs in Women with Lung Adenocarcinoma.

Wu S, Tu Q, Yuan H, Wu Z, Yang Y, Chen C Biochem Genet. 2023; 62(4):2702-2720.

PMID: 37999876 DOI: 10.1007/s10528-023-10572-w.

Molecular docking analysis of VEGF with compounds from tomato.

Krishnan M, Babu S, Thomas S, Surulivel J, Ayyanar K Bioinformation. 2023; 18(5):478-481.

PMID: 36945221 PMC: 10024781. DOI: 10.6026/97320630018478.

Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India.

Anthony M, Chowdhury N, Mishra M, Tale S, Arathi K, Rao S Cureus. 2022; 14(5):e25243.

PMID: 35755570 PMC: 9217682. DOI: 10.7759/cureus.25243.

The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis.

Xu W, Cui J, Wu L, He C, Chen G Toxicol Appl Pharmacol. 2021; 426:115633.

PMID: 34166680 PMC: 8338898. DOI: 10.1016/j.taap.2021.115633.

References

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Hodi F, Butler M, Oble D, Seiden M, Haluska F, Kruse A . Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008; 105(8):3005-10. PMC: 2268575. DOI: 10.1073/pnas.0712237105. View

Schiller J, Levitt M . Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol. 1995; 18(1):47-51. DOI: 10.1097/00000421-199502000-00010. View

Ngiow S, Von Scheidt B, Akiba H, Yagita H, Teng M, Smyth M . Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011; 71(10):3540-51. DOI: 10.1158/0008-5472.CAN-11-0096. View

Sugamura K, Ishii N, Weinberg A . Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004; 4(6):420-31. DOI: 10.1038/nri1371. View

Zheng H, Li Y, Wang X, Zhang X, Wang X . [Expression and significance of gp96 and immune-related gene CTLA-4, CD8 in lung cancer tissues]. Zhongguo Fei Ai Za Zhi. 2010; 13(8):790-4. PMC: 6000562. DOI: 10.3779/j.issn.1009-3419.2010.08.08. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

Giaccone G, Bazhenova L, Nemunaitis J, Tan M, Juhasz E, Ramlau R . A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015; 51(16):2321-9. DOI: 10.1016/j.ejca.2015.07.035. View

10.

Sabatos C, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng X . Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003; 4(11):1102-10. DOI: 10.1038/ni988. View

11.

Chen Y, Wang L, Zhu H, Li X, Zhu Y, Yin Y . Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J. 2013; 28(3):147-51. DOI: 10.1016/s1001-9294(13)60040-1. View

12.

Zhou Q, Munger M, Veenstra R, Weigel B, Hirashima M, Munn D . Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117(17):4501-10. PMC: 3099570. DOI: 10.1182/blood-2010-10-310425. View

13.

Maker A, Yang J, Sherry R, Topalian S, Kammula U, Royal R . Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006; 29(4):455-63. PMC: 2134804. DOI: 10.1097/01.cji.0000208259.73167.58. View

14.

Sabel M, Yamada M, Kawaguchi Y, Chen F, Takita H, Bankert R . CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother. 2000; 49(2):101-8. PMC: 11036983. DOI: 10.1007/s002620050608. View

15.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

16.

Lynch T, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R . Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30(17):2046-54. DOI: 10.1200/JCO.2011.38.4032. View

17.

Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L . Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009; 114(13):2667-77. PMC: 2756126. DOI: 10.1182/blood-2009-02-206532. View

18.

Sica G, Choi I, Zhu G, Tamada K, Wang S, Tamura H . B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003; 18(6):849-61. DOI: 10.1016/s1074-7613(03)00152-3. View

19.

Oxnard G, Morris M, Hodi F, Baker L, Kris M, Venook A . When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012; 104(20):1534-41. PMC: 3708548. DOI: 10.1093/jnci/djs353. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View